<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Clayton SW</submitter><funding>National Institutes of Health</funding><funding>NIAMS NIH HHS</funding><funding>NIH HHS</funding><pagination>21364</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7721728</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(1)</volume><pubmed_abstract>Previously, we showed that embryonic deletion of TGF-β type 2 receptor in mouse sclerotome resulted in defects in fibrous connective tissues in the spine. Here we investigated how TGF-β regulates expression of fibrous markers: Scleraxis, Fibromodulin and Adamtsl2. We showed that TGF-β stimulated expression of Scleraxis mRNA by 2 h and Fibromodulin and Adamtsl2 mRNAs by 8 h of treatment. Regulation of Scleraxis by TGF-β did not require new protein synthesis; however, protein synthesis was required for expression of Fibromodulin and Adamtsl2 indicating the necessity of an intermediate. We subsequently showed Scleraxis was a potential intermediate for TGF-β-regulated expression of Fibromodulin and Adamtsl2. The canonical effector Smad3 was not necessary for TGF-β-mediated regulation of Sclera</pubmed_abstract><journal>Scientific reports</journal><pubmed_title>Canonical and noncanonical TGF-β signaling regulate fibrous tissue differentiation in the axial skeleton.</pubmed_title><pmcid>PMC7721728</pmcid><funding_grant_id>R56 AR053860</funding_grant_id><funding_grant_id>T32 AR069516</funding_grant_id><funding_grant_id>R01 AR053860</funding_grant_id><pubmed_authors>Ban GI</pubmed_authors><pubmed_authors>Liu C</pubmed_authors><pubmed_authors>Serra R</pubmed_authors><pubmed_authors>Clayton SW</pubmed_authors></additional><is_claimable>false</is_claimable><name>Canonical and noncanonical TGF-β signaling regulate fibrous tissue differentiation in the axial skeleton.</name><description>Previously, we showed that embryonic deletion of TGF-β type 2 receptor in mouse sclerotome resulted in defects in fibrous connective tissues in the spine. Here we investigated how TGF-β regulates expression of fibrous markers: Scleraxis, Fibromodulin and Adamtsl2. We showed that TGF-β stimulated expression of Scleraxis mRNA by 2 h and Fibromodulin and Adamtsl2 mRNAs by 8 h of treatment. Regulation of Scleraxis by TGF-β did not require new protein synthesis; however, protein synthesis was required for expression of Fibromodulin and Adamtsl2 indicating the necessity of an intermediate. We subsequently showed Scleraxis was a potential intermediate for TGF-β-regulated expression of Fibromodulin and Adamtsl2. The canonical effector Smad3 was not necessary for TGF-β-mediated regulation of Sclera</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Dec</publication><modification>2025-04-19T06:54:51.841Z</modification><creation>2025-04-19T06:54:51.841Z</creation></dates><accession>S-EPMC7721728</accession><cross_references><pubmed>33288795</pubmed><doi>10.1038/s41598-020-78206-4</doi></cross_references></HashMap>